Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.

Front Oncol · 2024 · PMC11772297 · PMID 39876896

Europe PMC DOI

hedged sentence

0.0280

closest p · 0.6× alpha

0.0280

boldest claim

The sentences

a significant trendP = 0.028actually significant

Subgroup analysis based on ER status showed CA125 response rates of 0% (immunoscore of 150-199), 12% (immunoscore of 200-249), and 33% (immunoscore of 250-300), with a significant trend observed (P = 0.028, χ2 for trend).

also in 6,248 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.